Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/67944
Title: Fetal Down syndrome screening models for developing countries; Part II: Cost-benefit analysis
Authors: Chanane Wanapirak
Piyaluk Buddhawongsa
Woraluck Himakalasa
Auttapan Sarnwong
Theera Tongsong
Keywords: Medicine
Issue Date: 27-Nov-2019
Abstract: © 2019 The Author(s). Background: To identify the most cost-beneficial model as a national policy of screening and diagnosis of fetal Down syndrome (DS) in developing countries. Methods: Cost-benefit analysis (CBA) was performed based on the effectiveness and probabilities derived from a large prospective study on MSS (maternal serum screening) among Thai population. Various models including maternal age alone, STS (second trimester screen), I-S (independent screen: first or second trimester screen depending on the time of first visit), C-S (contingent serum screen) plus STS, maternal age with NIPS (non-invasive prenatal test), STS alone with NIPS, I-S with NIPS, C-S plus STS with NIPS, and Universal NIPS were compared. Results: I-S with NIPS as a secondary screening was most cost-beneficial (Benefit/Cost ratio 4.28). Cost-benefit is directly related to the costs of NIPS. Conclusion: In addition to simplicity and feasibility, I-S with expensive NIPS as a secondary screening is the most cost-beneficial method for low resource settings and should be included in universal healthcare coverage as a national policy. This study could be a model for developing countries or a guideline for international health organizations to help low resource countries, probably leading to a paradigm shift in prenatal diagnosis of fetal DS in the developing world.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85075721483&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/67944
ISSN: 14726963
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.